Asia-Pacific Liquid Biopsy Market

Asia-Pacific Liquid Biopsy Market Size

The liquid biopsy market size in Asia-Pacific was valued at USD 301.39 million in 2023. The Asia-Pacific market is predicted to experience a CAGR of 31.23% from 2024 to 2032 and be worth USD 3478.7 million by 2032 from USD 395.5 million in 2024.

Liquid biopsy is a technique that satisfies patients with the best treatment and also doctors by providing potential screening for disease. In addition, molecular characterization of the tumor can also be done by liquid biopsy. It provides ease of repeat sampling for monitoring genetic changes as the procedure is non-invasive.

MARKET DRIVERS

Medical communities are extending support for the market, which is acting as a key driver. The liquid biopsy technique is under advancement and is continuously improving, helping drive its adoption in clinical applications. Many new technologies are coming up in the market, such as cell capturing, sample preparation, and DNA amplification, making significant progress.

The test detects cancer accurately with a simple blood test. Liquid Biopsy has a tremendous positive impact on the fight against cancer by reducing the limitations of traditional biopsies. In India, for the first time in the world, tested 20,000 known cancer pathways at Apollo. Around 73% of patients were detected with ctDNA. In India, Neuroendocrine tumors are slow in growth, but they will spread very quickly. GALLIUM 68 SCAN allows surgeons to find the tumor's location. These techniques will promote the liquid biopsy market in the future. The adoption of advanced technology in the medical sector and the launch of innovative products to diagnose cancer at an early stage is accelerating the regional market growth.

MARKET RESTRAINTS

However, the rise in technological competition is acting as a restraint for the market.

GEOGRAPHICAL ANALYSIS

The Asia-Pacific liquid biopsy market is projected to grow highest during the forecast period, primarily due to the increasing focus of players in this region. In addition, India and China are the emerging countries in the Asia-Pacific region. They are expected to grow fast because of increased market access of each country’s population to healthcare resources.

KEY MARKET PLAYERS

Some promising companies operating in the APAC Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

In China, there are limitations, and liquid Biopsies cannot detect all cancer biomarkers, according to some research institutes. China needs more investigations and further validations. However, the demand for biomarkers in tumor samples is increasing. Research on liquid biopsies going on in the country will create chances for successful business in the future. Increasing chronic disease incidents and present cancer patients will drive the market in the coming years. 

Ministries of Health, Labor, and Welfare in Japan have granted marketing and manufacturing of the products used for blood circulating tumor ctDNA molecular testing for colorectal cancer patients. Ongoing research and development programs and the rising number of patients are the major drivers of the liquid biopsy market in Japan.

Australian researchers say that liquid biopsies might be used to treat cancer on a large scale. The clinical labs in Australia are proud to aid clinicians and assist patients by using advanced technology and a personalized medicine approach. It is also beneficial for lung and melanoma patients. So, the liquid biopsy market will grow in the future because of the increasing patient count and new players' investments in the market.

In South Korea, biotech companies commercialize the DNA-based liquid biopsy market and enable early cancer detection, precise treatment, and prognostic assessment. The number of patients who have been identified as familial cancer genes with high penetrance will drive the market in the future. Spreading awareness of this market is a challenge for companies. Client relationships and new research are expected to drive market growth in the forecast period.

MARKET SEGMENTATION

This research report on the Asia-Pacific liquid biopsy market is segmented and sub-segmented market into the following categories.

By Cancer Type 

• Lung Cancer
• Pancreatic Cancer
• Leukemia
• Other Visceral Cancers

By Diagnostic Approach 

• Circulating Tumour cells (CTC)
• Circulating Tumour DNA (ctDNA)
• RNA in exosomes
• Extra-Cellular Vesicles

By End-Users 

• Reference Laboratories
• Hospital/Physician Laboratories
• Academic and Research Centers
• Other End Users

By Country 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of Asia-Pacific